Waxing and waning of MET amplification in EGFR mutated NSCLC in response to presence and absence of erlotinib selection pressure

Παρόμοια τεκμήρια

• Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
  ανά: Seki, Nobuhiko, κ.ά.
  Έκδοση: (2019)
• Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC
  ανά: Turke, Alexa B., κ.ά.
  Έκδοση: (2010)
• MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
  ανά: Jakobsen, K R, κ.ά.
  Έκδοση: (2017)
• MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
  ανά: Presutti, Dario, κ.ά.
  Έκδοση: (2015)
• MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
  ανά: Kubo, Takafumi, κ.ά.
  Έκδοση: (2009)